Sigilon Therapeutics



Sigilon Therapeutics’ mission is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases.


Add photos to showcase Sigilon Therapeutics’s culture


Add Sigilon Therapeutics’s values

Insider experiences

Share your experience of working at Sigilon Therapeutics

Rogerio Vivaldi Coelho
President and CEO
Matthew Kowalsky
Chief Legal Officer
Philip Ashton-Rickardt
Chief Scientific Officer
Josias Pontes
VP, Head of Finance
Susan Drapeau
VP, Head of Device and Delivery Engineering
Robert Windsor Jr.
VP, Head of Investor Relations
Jiang Wu
VP, Head of Bioanalytical & CMC Analytical Development
Bernd Kullmann
VP, Head of Manufacturing & Supply Chain
Ajay Rai
SVP, Head of Business Development
Olivia G. Kelly
VP, Head of Islet Cell Therapy Research

Add your teams to show how people work together at Sigilon Therapeutics

Add jobs to your org chart to show candidates who they’ll work with

Publish company announcements to get more exposure